文献速递腹部USMR

监测超声发现肝细胞癌结节:CEUS与MRI作为初始检查的比较

Nodules Identified on Surveillance Ultrasound for HCC: CEUS or MRI as the Initial Test?
PubMed 文献 · J Ultrasound Med · 2023-02-20

该前瞻性研究纳入195例监测超声阳性的高危患者,均行CEUS和MRI,以活检或随访为金标准。CEUS确认监测超声所见优于MRI(97% vs 79%),诊断恶性肿瘤敏感度81%、特异度92%,MRI分别为64%和93%,CEUS对监测超声阳性病灶的初始评估至少不劣于MRI。

要点

  • 监测超声阳性后,CEUS在确认病灶与超声所见一致性上优于MRI。
  • CEUS诊断恶性肿瘤敏感度81%、特异度92%,MRI为64%和93%。
  • CEUS可通过廓清表现将MRI LR-3/4病灶升级为LR-5或LR-M。

核心结论

  • CEUS对监测超声阳性病灶的初始评估至少与MRI等效,甚至更优。

研究设计与样本

  • 前瞻性研究,经机构审查委员会批准,连续纳入195例监测超声阳性的高危患者,均行CEUS和MRI,以活检(n=44)和随访为金标准。

关键影像表现/征象

  • CEUS与监测超声所见相关189/195(97%),MRI相关153/195(79%)。
  • MRI阴性者中,CEUS诊断2例HCC和1例iCCA并经活检证实。
  • CEUS与MRI结果一致146/195(75%),其中恶性57例、良性89例。
  • 不一致时,CEUS通过显示MRI未显示的廓清,将20例MRI LR-3/4升级为LR-5或LR-M(10例活检证实)。
  • CEUS根据廓清时间和强度诊断13/20例LR-5为晚且弱廓清、7例LR-M为快且明显廓清。

诊断标准与关键数值

  • CEUS诊断恶性肿瘤敏感度81%、特异度92%;MRI敏感度64%、特异度93%。
  • MRI和CEUS结果按LI-RADS分类和患者结局分类。
  • 全组71例恶性诊断,包括58例LR-5(MRI 45例、CEUS 54例)和13例其他,含非LR-5的HCC和活检证实的LR-M iCCA(MRI 3例、CEUS 6例)。
  • 一致结果中LR-5 41/57、LR-M 6/57。

临床应用与阅片要点

  • 监测超声阳性后可用CEUS作为初始进一步检查,减少对MRI的依赖。
  • CEUS显示廓清可将MRI分类不足的病灶升级,注意观察廓清时间和强度。
  • MRI阴性时仍应警惕CEUS可检出HCC或iCCA。

局限性

  • 单中心前瞻性研究,样本量195例,活检仅44例,其余以随访为参考标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Following positive surveillance ultrasound (US), magnetic resonance imaging (MRI) is recommended for further characterization. We propose contrast-enhanced ultrasound (CEUS) shows equivalent efficacy.

METHODS: This prospective institutional review board approved study recruited 195 consecutive at-risk patients with a positive surveillance US. All had CEUS and MRI. Biopsy (n = 44) and follow-up are gold standard. MRI and CEUS results are classified according to liver imaging reporting and data system (LI-RADS) and patient outcome.

RESULTS: As an US-based modality, CEUS is superior in confirming findings from surveillance US, correlation in 189/195 (97%) on CEUS compared to 153/195 (79%) on MRI. Within these negative MRI examinations, there are 2 hepatocellular carcinoma (HCC) and 1 cholangiocarcinoma (iCCA) diagnosed on CEUS and proven by biopsy. From 195 patients, there are 71 malignant diagnoses from all sources, including 58 LR-5 (45 on MRI and 54 on CEUS) and 13 others, including HCC outside of LR-5 category, and LR-M with biopsy proven iCCA (3 on MRI and 6 on CEUS). CEUS and MRI show concordant results in the majority of patients (146/195, 75%), including 57/146 malignant and 89/146 benign diagnoses. There are 41/57 concordant LR-5 and 6/57 concordant LR-M. When CEUS and MRI are discordant, CEUS upgraded 20 (10 biopsy-proven) from MRI LR-3/4 to CEUS LR-5 or LR-M by showing washout (WO) that MRI failed to show. Additionally, CEUS characterized time and intensity of WO and diagnosed 13/20 LR-5 by showing late and weak WO and 7 LR-M by showing fast and marked WO. CEUS is 81% sensitive and 92% specific in diagnosing malignancy. MRI is 64% sensitive and 93% specific.

CONCLUSIONS: CEUS performance is at least equivalent if not superior to MRI for initial evaluation of lesions from surveillance US.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Hu, Burrowes, Caine, et al. Nodules Identified on Surveillance Ultrasound for HCC: CEUS or MRI as the Initial Test? J Ultrasound Med. 2023. PMID: 36807925. doi:10.1002/jum.16183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。